Figure 2
Moving quantiles analyses for calculation of continuous references for pediatric-specific BCR::ABL1 transcript monitoring. (a) Monitoring of individual BCR::ABL1 transcript levels of all patients during TKI. (b) Moving quantiles based on BCR::ABL1 transcript numbers of all patients (gray) or optimal responders (green) plotted over the first 3 years of TKI therapy. The dark-colored lines represent the median (50-Q.). Light-colored lines present the 25-Q. and the 75-Q. (c) Visualization of ELN criteria over the first 3 years of TKI therapy. The green area marks optimal therapy response, the yellow area indicates warning and the red area represents therapy failure. (d) Continuous references based on moving quantiles analyses of optimal responders over the first 3 years of TKI therapy. The smoothed graphs illustrate the 25-Q. (green line), 50-Q. (grey line), 75-Q. (orange line) and 95-Q. (red line). The light and dark green areas represent an above-average MR (optimal response), the yellow area a slightly below-average MR (observation range), and the red area a non-optimal MR (poor response). Q. quantile.
